Omnicell, Inc. (OMCL)
| Market Cap | 7.32B |
| Revenue (ttm) | 987.48M |
| Net Income (ttm) | 59.73M |
| Shares Out | 43.26M |
| EPS (ttm) | 1.32 |
| PE Ratio | 126.35 |
| Forward PE | 37.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 163,022 |
| Open | 166.76 |
| Previous Close | 167.10 |
| Day's Range | 165.91 - 168.69 |
| 52-Week Range | 82.01 - 168.69 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 170.11 (+1.7%) |
| Est. Earnings Date | Nov 2, 2021 |
About OMCL
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides p...
Financial Performance
In 2020, Omnicell's revenue was $892.21 million, a decrease of -0.54% compared to the previous year's $897.03 million. Earnings were $32.19 million, a decrease of -47.51%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Omnicell stock is "Buy." The 12-month stock price forecast is 170.11, which is an increase of 1.69% from the latest price.
News
CNVY vs. OMCL: Which Stock Should Value Investors Buy Now?
CNVY vs. OMCL: Which Stock Is the Better Value Option?
Omnicell to Release Third Quarter 2021 Financial Results on November 2, 2021
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its fi...
Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges
Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.
Omnicell (OMCL) Soars 3.4%: Is Further Upside Left in the Stock?
Omnicell (OMCL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...
Omnicell (OMCL) Soars to 52-Week High, Time to Cash Out?
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
FDS Amplicare Hosts Webinar to Advise Pharmacists on Assisting Customers During Medicare Open Enrollment
FORT WORTH, Texas, Oct. 6, 2021 /PRNewswire/ -- FDS Amplicare, which builds industry-leading SaaS technology solutions that strengthen the health of retail pharmacies and their patients, today announced...
3 Reasons Growth Investors Will Love Omnicell (OMCL)
Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
CPSI vs. OMCL: Which Stock Is the Better Value Option?
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Here's Why You Should Add Omnicell (OMCL) to Your Portfolio
Investors continue to be optimistic about Omnicell (OMCL) on its strategic acquisitions and partnerships supporting each of the three legs of its strategy.
Omnicell (OMCL) New Buyout Expands Patient Engagement Suite
With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.
Omnicell Completes Acquisition of FDS Amplicare
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Completes Acquisition of FDS Amplicare
Is Omnicell (OMCL) a Solid Growth Stock? 3 Reasons to Think " Yes "
Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 MedTech Sectors Benefiting Despite COVID-19 Resurgence
Here we discuss three major subsectors of MedTech and some of their constituent stocks for which COVID-19 has opened up enormous growth prospects.
Omnicell (OMCL) Opens New Software Development Center in India
Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.
Omnicell Grows International Footprint with Opening of Omnicell India Software Development Center
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced it has ...
4 MedTechs to Gain in 2H21 Beating the Delta Variant-Led Dip
Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.
Omnicell (OMCL) Enhances Medication Management With New Release
Omnicell's (OMCL) Summer 2021 Release offers greater platform deployment options, providing customers better flexibility and improving time to value for strategic initiatives.
CPSI vs. OMCL: Which Stock Is the Better Value Option?
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Looking for a Growth Stock? 3 Reasons Why Omnicell (OMCL) is a Solid Choice
Omnicell (OMCL) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Add Omnicell (OMCL) to Your Portfolio
Omnicell (OMCL) ended the second quarter with better-than-expected results, with the top line registering solid year-over-year growth.
Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology-Enabled Services with Summer 2021 ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced its lat...
Omnicell (OMCL) Rides on New Buyout, Innovation Amid Pandemic
Omnicell (OMCL) accelerates shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services.
Is Omnicell (OMCL) a Solid Growth Stock? 3 Reasons to Think " Yes "
Omnicell (OMCL) possesses solid growth attributes, which could help it handily outperform the market.
Omnicell (OMCL) Hits 52-Week High, Can the Run Continue?
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.